safety of glp 1 receptor agonists Understanding GLP-1 and their impact on drug discovery GLP-1 receptor agonists in pediatric

The FDA recommends talking with your healthcare provider before considering them

Jonesboro, Arkansas, United States: StatPearls (2024)

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimers disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

These agents now play a central role not only in weight management and diabetes care but are also being investigated in a growing number of conditions, including cardiovascular, renal, hepatic, neurologic, and substance use disorders

Every current candidate continues to utilize GLP-1R agonism as a cornerstone component (Table 1)

Highlight cardioprotective mechanisms of action of GLP-1 agonist